Dermagraft deal extended to venous applications
This article was originally published in Clinica
Advanced Tissue Sciences and Smith & Nephew have expanded their 50:50 joint venture to include the development and marketing of Dermagraft for venous ulcers, pressure sores, burns and other wounds. The new agreement is valid worldwide except for the US and also covers the marketing of Dermagraft TC, a temporary covering for partial and full-thickness burns.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.